IPSO will host an in-person Congress on March 22-24th, 2024 in Toronto, Canada at the Hospital for Sick Children. The mission of this Congress is to unify the global community of professionals engaged in research and clinical care for children with cerebrovascular diseases, and chart a path forward for multinational, multidisciplinary efforts.
We would like to express gratitude to our following sponsors for their generous support to the 2024 IPSO Congress.
2024 IPSO Congress Partnerships
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. The Bayer brand stands for trust, reliability and quality throughout the world.
Founded in 2018, the Moyamoya Foundation (aka MoyaMoya Foundation Co) is a disease focused 501(c)(3) non-profit foundation. Moyamoya vasculopathy is a rare, progressive group of diseases in which the main arteries supplying the brain with blood (the internal carotid arteries and intracranial branches) narrow overtime and collateral vessels called “moyamoya vessels” develop as an attempt to compensate for the lack of blood flow. Moyamoya patients are at increased risk for stroke, among other neurological complications. Currently, the typical intervention for moyamoya patients is revascularization surgery.
We are a fully volunteer organization consisting of many moyamoya patients, caregivers, and others with personal connections to moyamoya disease. We are managed by a six-member Board of Directors and our primary funding comes from donations through social media and our website.
Our mission is to promote awareness of moyamoya and advance moyamoya research through collaboration with healthcare professionals and academics about research priorities for moyamoya patients. We also provide assistance to families and patients undergoing moyamoya treatment.
We recently launched the “Global Moyamoya Patient Registry”, a collective effort to gather comprehensive data about this rare disease. Patients can securely share important data such as, demographics, symptoms, treatments, family history, and unique experiences of living with a rare disease, such as delays in diagnosis, misdiagnosis, and travel considerations for specialty care. This collection of data will be used by researchers to improve outcomes for patients.
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries.
At Scientia Vascular, we believe that without access, therapy can not exist. Through cutting-edge innovation, we’re answering our calling to radically disrupt the way diseases of the brain are treated. Our teams have been at the forefront of neurovascular systems, pushing beyond established boundaries to deliver the products physicians and patients need most.
Children's Medical Center Dallas
Children’s Medical Center Dallas, the flagship hospital of Children’s Health, is the home of the Center for Cerebrovascular Disorders in Children, which provides a multidisciplinary approach to children with complex, often life-threatening disorders that impact or cause injury to the blood vessels that supply the brain. As the only Center of its kind in Texas and one of a handful across the nation, we offer an unmatched level of experience. Our expert team specializes in neurointerventional radiology, neurosurgery, neurology, neurologic critical care and neuro-anesthesia. From strokes and arteriovenous malformations to vein of Galen malformations, Moyamoya disease and cerebral venous thrombosis, we work one-on-one with patients to assess, evaluate, manage and treat conditions..
Sickkids: Neurosciences and Mental Health (NMH)
We are uncovering innovative solutions for mitigating and curing brain diseases in children.The Neurosciences & Mental Health research program focus on the development and plasticity of complex neural systems in animal models and humans through a variety of approaches including molecular genetics, electrophysiology, behavior, cognition and neuroimaging. As a leader in paediatric neurosciences and mental health, and a hub of discovery for applied mental health research at SickKids, we’ve made a number of important research discoveries and published high-impact papers, translating our work into better health outcomes for children and youth.
Sickkids: Research Institute
The SickKids Research Institute (RI) is Canada’s largest, hospital-based child health research institute conducting and translating groundbreaking research, training the next generation of researchers, and supporting global scientific communities with knowledge and state-of-the-art facilities. We’re taking more discoveries from the lab bench to the bedside, making a bigger impact on children’s lives around the world, sooner.
Why Partner with IPSO?
Connect with leading clinicians & researchers. Increase your visibility with key decision makers and engage with a global organization emphasizing work on pediatric stroke and cerebrovascular disease
Support those helping children, by the emphasizing the important work on pediatric stroke and cerebrovascular disease. The greatest benefit of IPSO partnership.
Promote your brand by highlighting your products and services to a growing, influential community. Choose a sponsor ship level to fit your budget and start promoting to the people that matter.